Mercy George
Primary Care · Queen Creek, AZNPI 1831705524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$563
- BETA Bionics, Inc.$551
- Bayer$330
- Xeris Pharmaceuticals, Inc.$280
- Dexcom, Inc.$255
- Sanofi-aventis U.S. LLC$251
- plus $3K from 28 others
What the payments were for
- Food & beverage$4,74099%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $563 |
| BETA Bionics, Inc. | 33 | $551 |
| Bayer | 16 | $330 |
| Xeris Pharmaceuticals, Inc. | 16 | $280 |
| Dexcom, Inc. | 12 | $255 |
| Sanofi-aventis U.S. LLC | 11 | $251 |
| AstraZeneca | 9 | $220 |
| Recordati_rare_diseases_inc. | 10 | $212 |
| Averitas Pharma Inc. | 14 | $200 |
| Mannkind Corporation | 15 | $188 |
| Radius Health, Inc. | 12 | $183 |
| Corcept Therapeutics | 9 | $177 |
| Insulet Corporation | 8 | $165 |
| Novo Nordisk | 8 | $149 |
| Ascendis Pharma Endocrinology Inc | 6 | $142 |
| Gilead | 1 | $116 |
| Amgen | 6 | $103 |
| Medtronic | 5 | $92 |
| Amneal Pharmaceuticals LLC | 4 | $78 |
| Antares Pharma, Inc. | 4 | $76 |
| Almatica Pharma LLC | 3 | $71 |
| Boehringer Ingelheim | 3 | $52 |
| AbbVie | 3 | $51 |
| Abbott | 3 | $48 |
| Soleno Therapeutics, Inc. | 1 | $29 |
| Cequr Corporation | 1 | $25 |
| IBSA Pharma Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$105
How this compares
$4,764 in reported general payments places this provider in the 90th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $279,940 |
| TrulicityDulaglutide | 63 | $113,418 |
| MounjaroTirzepatide | 62 | $99,525 |
| JardianceEmpagliflozin | 70 | $73,617 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $33,203 |
| FarxigaDapagliflozin Propanediol | 21 | $20,301 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $19,466 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $18,197 |
| Humalog Kwikpen U-100Insulin Lispro | 29 | $14,978 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $12,098 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $9,614 |
| HumalogInsulin Lispro | 23 | $8,518 |
| Novolog FlexpenInsulin Aspart | 26 | $7,594 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $6,957 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $5,419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $149 | $279,940156 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $563 | $223,712163 claims |
| Boehringer IngelheimJardiance | $52 | $73,61770 claims |
| AstraZenecaFarxiga | $220 | $20,30121 claims |
| Sanofi-aventis U.S. LLCLantus | $251 | $4,32416 claims |
| AbbVieSynthroid | $51 | $2,49427 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $78 | $2,103191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 151 primary care providers in Arizona.
Other primary care in Queen Creek
- Katy DodtQueen Creek$5K
- Britney FerreraQueen Creek$4K
- Tammy ChesleyQueen Creek$1K
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Neena VargheseSacaton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.